Press Release
Sep 13, 2018
The International Association for the Study of Lung Cancer to Present IASLC Merit Award to Françoise Mornex
DENVER, September 13, 2018 – Professor Françoise Mornex, M.D., Ph.D., will be recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. Dr. Mornex will accept the IASLC Merit Award, honoring her extraordinary contributions to the development of the Association.
Professor Mornex is a professor of oncology at the University Claude Bernard in Lyon, France, and past-chair of the Radiation Oncology Department at the Centre Hospitalier Lyon Sud, where she practices radiotherapy and medical oncology. Her work is focused in the field of combined chemoradiation, where she has assumed a leadership role in the development of multi-modal treatment for lung and digestive tract tumors. Her current research interests include the development of new chemoradiation treatments and the design of phase I, II and III randomized trials, including the recent implementation of immunotherapy.
“Professor Françoise Mornex has served the IASLC in a range of roles over many years. She has inspired many younger colleagues to join the field and to join the IASLC,” said Fred R. Hirsch, M.D., Ph.D., CEO of the IASLC. “We feel honored to acknowledge Professor Mornex’s contribution to the IASLC with this Distinguished Award.”
Professor Mornex joined the IASLC in 1987 and served on its Board of Directors from 2013-2017. She has organized many national and international meetings, including multiple IASLC lung cancer workshops. She was the co-president of the highly successful first and second European IASLC-ESMO lung cancer conferences in Geneva in 2008 and 2010. She is the general secretary and a member of the French Radiation Oncology Society (SFRO), as well as a member of the American Society for Therapeutic Radiology and Oncology (ASTRO) and Intergroupe Françophone de Cancérologie Thoracique (IFCT), among others. An accomplished scientist, Professor Mornex has published over 290 articles, two books and several book chapters on lung cancer.
Professor Mornex graduated from the University Claude Bernard with a Ph.D. and a M.D. and a Habilitation to Direct Research. She also completed a two-year fellowship in radiation oncology and research at the National Cancer Institute, a part of the National Institutes of Health, in Bethesda, Maryland.
Professor Mornex will be honored on September 23, 2018 at the Opening Plenary Session at the IASLC 19th WCLC in Toronto, Canada. The IASLC WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The IASLC 19th WCLC will take place in Toronto on September 23-26, 2018. The Distinguished Awards are presented each year at the WCLC to the IASLC scientists who have demonstrated excellence in the field of lung cancer research and prevention.
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit www.iaslc.org. Follow the conference on social media with: #WCLC2018.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.